Download Possible Applications Basic overview

Therapeutic For Inflammatory &
Autoimmune Diseases
Basic overview
Possible Applications
With nearly 20% of the developed world suffering or developing
autoimmune and inflammatory related diseases and with no
known cure, there is a growing and urgent need for more
specific and effective therapeutics. Researchers from Trinity
College Dublin have discovered a novel method of suppressing
the induction of a specific subtype of T cell responses in vivo,
which are fundamental players in autoimmune and
inflammatory related diseases, such as multiple sclerosis (MS),
rheumatoid arthritis (RA), ulcerative colitis and allergies.
The specificity of the technology is far superior to current
treatments which involve non specific therapies with significant
side effects such as non-steroidal anti-inflammatory (NSAID)
drugs. Whilst they ameliorate symptoms of the disease, they
do not prevent the progression of the disease.
What Problem does it Solve/Advantages
Can be used as a platform therapeutic to treat a variety of
autoimmune and inflammatory related diseases.
*
75
MEDIUM
Bp LPS 100 pg/ml
Bp LPS 1000 pg/ml
Bp LPS 10000 ng/ml
TCT 10 g/ml
TCT+Bp LPS 100pg/ml
TCT+Bp LPS1000pg/ml
TCT+Bp LPS10000pgml
***
50
750
IL-1 (pg/ml)
IL-10 (pg/ml)
100
500
**
0
1 HR PRETREATMENT
6 HRS PRETREATMENT
12 HRS PRETREATMENT
1 HR PRETREATMENT
6 HRS PRETREATMENT
12 HRS PRETREATMENT
1 HR PRETREATMENT
6 HRS PRETREATMENT
12 HRS PRETREATMENT
100
IL-12p70 (pg/ml)
IL-12p40 (pg/ml)
30000
20000
10000
0
50
0
1 HR PRETREATMENT
6 HRS PRETREATMENT
12 HRS PRETREATMENT
5000
(pg/ml)
20000
15000
10000
4000
**
3000
2000
1000
0
0
1 HR PRETREATMENT
6 HRS PRETREATMENT
12 HRS PRETREATMENT
1 HR PRETREATMENT
6 HRS PRETREATMENT
12 HRS PRETREATMENT
Technology and Patent Status
The efficacy of technology has been demonstrated in vivo, in
animal models of MS and shown to be extremely effective in
abrogating progression of the disease. The mechanism of
action underlying the TCT/Peptide inhibition of T cell subtype
is currently under investigation.
4
Clinical Score
**
250
0
5000
Control
TriDap-Treated
*
***
25
MIP-1
More recently, the Researchers have demonstrated the
immunosuppressive properties of another more potent TCTlike synthetic peptide molecule, which also has the ability to
specifically significantly reduce the induction of a population
of T cells in vitro and in vivo in the EAE model.
Both TCT and the synthetic analog are low molecular weight
molecules, allowing for the development of molecular
mimetics, with easy synthesis, scale up and delivery.
IL-6 (pg/ml)
The technology is part of an earlier discovery which
demonstrated that TCT, a virulence factor of Bordetella
pertussis, can bind intracellular pathogen recognition
receptors on innate immune cells. Parenteral administration
of TCT suppressed the induction of T cells responses directed
by dendritic cells in vitro and by direct administration with
antigens in vivo. In animal models of human diseases, TCT
attenuated acute graft-versus host disease and slowed the
onset and clinical signs of experimental autoimmune
encephalomyelitis (EAE), a mouse model of multiple
sclerosis.
Both molecules, TCT and the synthetic analog, specifically
target subtypes of T cells that are key players in autoimmune
and inflammatory diseases and thus are not likely to be
broadly immunosuppressive as with current broad spectrum
treatments.
3
Patent Publication Number WO07118901A2: Methods and
compositions for modulating an immune response.
2
The Opportunity
These high-growth-potential compounds have been
developed from their inception to be suitable for clinical
development and commercialisation.
1
0
0
10
20
Days post induction
30
Please do not hesitate to contact us if you would like to
collaborate in this area; there are various support
mechanisms and grants to avail of for furthering the
development of this technology.
Researchers: Prof. Kingston Mills & Dr. Sarah Higgins
Contact:
Dr. Emily Vereker, TTO Case Manager [email protected] + 353 1 896 4152
Ref:
KM01-051/166